AbCellera Acquires Lineage Biosciences

AbCellera expands its antibody discovery capabilities by capturing foundational repertoire sequencing technology from immune profiling start-up. 

Vancouver, Canada (August 1st, 2018)AbCellera Biologics Inc., a technology leader in therapeutic antibody discovery, has acquired Lineage Biosciences in an all-stock transaction. Through the acquisition, AbCellera expands its capabilities in antibody discovery and vaccine research by obtaining exclusive rights to foundational technology for immune repertoire sequencing.

Lineage Biosciences, a Palo Alto-based start-up, was founded based on technology for the profiling of antibody responses using next-generation sequencing of immunoglobulin genes (Ig-SEQ). Ig-SEQ enables deep analysis of antibodies generated by natural immune responses during infection, autoimmune disease, cancer, immunization, and vaccination.

Ig-SEQ was developed by Professor Stephen Quake’s research group at Stanford University, which licenses the technology to Lineage Biosciences. Ig-SEQ has been widely adopted as a platform for basic and translational immunology research and is increasingly being applied in industry to develop vaccines and to accelerate antibody discovery. Deep profiling of antibody repertoires complements the unique functional information obtained from AbCellera’s single B cell discovery platform, increasing the diversity of antibodies identified and enabling comprehensive analysis of immune responses over time.

“Through this acquisition, AbCellera has expanded its intellectual property estate into an important area. The addition of repertoire sequencing is strategic and complements our core microfluidic single-cell screening platform. It reinforces our technology advantage in antibody discovery and vaccine research,” commented Dr. Carl Hansen, CEO of AbCellera.

About AbCellera Biologics Inc. 

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans.

Find a complete list of news announcements on AbCellera’s online news feed, on LinkedIn and on Twitter @AbCelleraBio.

Kevin Heyries, PhD
Telephone: 604.559.9005




Together we can make game-changing discoveries.